Buscar
Roivant Sciences Ltd
ROIVAñadir a la lista de seguimiento
33.910USD
-0.610-1.77%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
24.43BCap. mercado
PérdidaP/E TTM
Más Datos de Roivant Sciences Ltd Compañía
Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
Información de Roivant Sciences Ltd
Símbolo de cotizaciónROIV
Nombre de la empresaRoivant Sciences Ltd
Fecha de salida a bolsaDec 03, 2020
Director ejecutivoVenker (Eric)
Número de empleados750
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 03
Dirección7Th Floor, 50 Broadway
CiudadLONDON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited Kingdom
Código postalSW1H 0DB
Teléfono4412955950
Sitio Webhttp://roivant.com/
Símbolo de cotizaciónROIV
Fecha de salida a bolsaDec 03, 2020
Director ejecutivoVenker (Eric)
Ejecutivos de Roivant Sciences Ltd
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Frank M. Torti, M.D.
Dr. Frank M. Torti, M.D.
President and Vant Chairman
President and Vant Chairman
13.54M
-0.30%
Dr. Keith S. Manchester, M.D.
Dr. Keith S. Manchester, M.D.
Independent Director
Independent Director
1.73M
-11.55%
Dr. Eric Venker, M.D.
Dr. Eric Venker, M.D.
President and Immunovant Chief Executive Officer
President and Immunovant Chief Executive Officer
1.46M
--
Ms. Jennifer Humes
Ms. Jennifer Humes
Chief Accounting Officer
Chief Accounting Officer
109.78K
-3.26%
Mr. Ilan Oren
Mr. Ilan Oren
Independent Chairman of the Board
Independent Chairman of the Board
102.42K
+0.76%
Mr. James C. (Jim) Momtazee
Mr. James C. (Jim) Momtazee
Independent Director
Independent Director
93.40K
+0.43%
Mr. Matthew Gline
Mr. Matthew Gline
Chief Executive Officer, Director
Chief Executive Officer, Director
82.26K
--
Mr. Richard Pulik
Mr. Richard Pulik
Chief Financial Officer
Chief Financial Officer
74.59K
-2.85%
Ms. Melissa B. Epperly
Ms. Melissa B. Epperly
Independent Director
Independent Director
611.00
+88.87%
Mr. Daniel Gold
Mr. Daniel Gold
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Frank M. Torti, M.D.
Dr. Frank M. Torti, M.D.
President and Vant Chairman
President and Vant Chairman
13.54M
-0.30%
Dr. Keith S. Manchester, M.D.
Dr. Keith S. Manchester, M.D.
Independent Director
Independent Director
1.73M
-11.55%
Dr. Eric Venker, M.D.
Dr. Eric Venker, M.D.
President and Immunovant Chief Executive Officer
President and Immunovant Chief Executive Officer
1.46M
--
Ms. Jennifer Humes
Ms. Jennifer Humes
Chief Accounting Officer
Chief Accounting Officer
109.78K
-3.26%
Mr. Ilan Oren
Mr. Ilan Oren
Independent Chairman of the Board
Independent Chairman of the Board
102.42K
+0.76%
Mr. James C. (Jim) Momtazee
Mr. James C. (Jim) Momtazee
Independent Director
Independent Director
93.40K
+0.43%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Roivant Sciences Ltd?
Los cinco principales accionistas de Roivant Sciences Ltd son: Dr. Frank M. Torti, M.D.
¿Cuántas instituciones poseen acciones de Roivant Sciences Ltd (ROIV)?
A fecha de 2026Q1, 781 instituciones poseen acciones de Roivant Sciences Ltd, con un valor de mercado combinado de aproximadamente 565.52M, lo que representa el 79.01% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -23023750.00.